Conference Reports

Madrid
28 September 2019 - 02 October 2019
Barcelona
27 September 2019 - 01 October 2019
Barcelona, Spain
16 September 2019 - 20 September 2019
San Francisco, California, US
25 September 2019 - 29 September 2019
Mexico City, Mexico
21 July 2019 - 24 July 2019
Philadelphia, Pennsylvania
11 July 2019 - 14 July 2019
Los Angeles, California, US
14 July 2019 - 18 July 2019
Madrid, Spain
12 June 2019 - 15 June 2019
San Francisco, California
07 June 2019 - 11 June 2019
Chicago, Illinois, US
31 May 2019 - 04 June 2019
Pasay City
22 May 2019 - 26 May 2019
Dallas, Texas, US
17 May 2019 - 22 May 2019
Philadelphia, Pennsylvania
04 May 2019 - 10 May 2019
Baltimore, Maryland
24 April 2019 - 01 May 2019
Amsterdam, The Netherlands
13 April 2019 - 16 April 2019
Geneva, Switzerland
10 April 2019 - 13 April 2019
Vienna, Austria
10 April 2019 - 14 April 2019
Atlanta, Georgia
29 March 2019 - 03 April 2019
Lisbon, Portugal
17 March 2019 - 19 March 2019
New Orleans, Louisiana
16 March 2019 - 18 March 2019
Washington DC, US
01 March 2019 - 05 March 2019
New Orleans, Louisiana, US
23 March 2019 - 26 March 2019
Honolulu, Hawaii, US
06 February 2019 - 08 February 2019
19 January 2019 - 20 January 2019
Orlando, Florida, US
13 December 2018 - 15 December 2018
Vienna, Austria
12 December 2018 - 15 December 2018
San Antonio, Texas
04 December 2018 - 08 December 2018
San Diego, California, US
01 December 2018 - 04 December 2018
Singapore
23 November 2018 - 25 November 2018
Kuala Lumpur
22 November 2018 - 25 November 2018
Chicago, Illinois, US
10 November 2018 - 12 November 2018
Munich
19 October 2018 - 23 October 2018
Bangkok, Thailand
28 September 2018 - 01 October 2018
Munich
25 August 2018 - 29 August 2018
Surabaya
08 August 2018 - 11 August 2018
Amsterdam, the Netherlands
23 July 2018 - 27 July 2018
Orlando, Florida, US
22 June 2018 - 26 June 2018
Stockholm, Sweden
14 June 2018 - 17 June 2018
Amsterdam
13 June 2018 - 16 June 2018
San Diego, California, US
18 May 2018 - 23 May 2018
Los Angeles, California, US
21 April 2018 - 27 April 2018
Chicago, Illinois, US
14 April 2018 - 18 April 2018
Geneva
11 April 2018 - 14 April 2018
Barcelona
18 March 2018 - 20 March 2018
Chicago, Illinois, US
16 March 2018 - 20 March 2018
Copenhagen
16 March 2018 - 19 March 2018
Hong Kong
10 March 2018 - 11 March 2018
Orlando, Florida
10 March 2018 - 12 March 2018
San Diego, California
16 February 2018 - 20 February 2018
Las Vegas, Nevada
18 January 2018 - 20 January 2018
Los Angeles, California, US
24 January 2018 - 26 January 2018
San Francisco, California, US
18 January 2018 - 20 January 2018
Hong Kong
20 January 2018 - 20 January 2018
Abu Dhabi
04 December 2017 - 08 December 2017
Atlanta, Georgia, US
09 December 2017 - 12 December 2017
San Antonio, Texas, US
05 December 2017 - 09 December 2017
Anaheim, California, US
11 November 2017 - 15 November 2017
Singapore
17 November 2017 - 19 November 2017
Singapore
06 October 2017 - 08 October 2017
Milan, Italy
09 September 2017 - 13 September 2017
Singapore
13 July 2017 - 15 July 2017
San Diego, California, US
09 June 2017 - 13 June 2017
Chicago, Illinois, US
02 June 2017 - 06 June 2017
Geneva
05 May 2017 - 08 May 2017
Houston, Texas, US
22 February 2017 - 24 February 2017
Amsterdam
27 January 2017 - 30 January 2017
San Diego, California
03 December 2016 - 06 December 2016
San Antonio, Texas
06 December 2016 - 10 December 2016
Vienna
04 December 2016 - 07 December 2016
12 November 2016 - 16 November 2016
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Aug 2019
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
20 Aug 2019
The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
Roshini Claire Anthony, 20 Aug 2019

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.